Feb 18, 2026Rapamycin in Older Adults: PEARL Trial Findings on Dose, Sex Differences, and Body CompositionThe PEARL trial tested low-dose weekly rapamycin in healthy older adults. The primary endpoint — visceral fat reduction — was not met. Secondary analyses suggested lean tissue effects at higher doses in women, but these require confirmation in adequately powered trials.
Feb 5, 2026mTOR, AMPK, and SIRT1: Longevity Pathway Switches and How Supplements Modulate ThemThree interlocked pathways — mTOR (growth/anabolism), AMPK (energy sensing), and SIRT1 (NAD-dependent deacetylase) — function as master longevity regulators. Supplements like rapamycin, berberine, and NMN modulate them through distinct entry points. Understanding the pathway logic prevents counterproductive stacking.
Feb 1, 2026Rapamycin and mTOR: Longevity Mechanism, PEARL Trial, and Low-Dose Protocol RisksRapamycin extends lifespan in every organism tested and the PEARL trial is the first human RCT for longevity use. mTOR inhibition reduces cellular senescence and improves immune function. Off-label use carries real risks that must be understood before consideration.